| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |